Careers  |  Sign In  |  Register

Latest in Oncology

An interim analysis of the CHECKMATE920 phase IIIb/IV clinical trial found that renal cell carcinoma (RCC) patients with brain metastasis show encouraging anti-tumor activity in response to nivolumab and ipilimumab. These findings, which were presented at the 2019 American Society of Clinical Oncology...
Results from the CARMENA trial, presented at the 2019 annual meeting of the American Society of Clinical Oncology suggest that cytoreductive nephrectomy should no longer be considered the standard care for metastatic renal cell carcinoma (RCC). With the exception of one subgroup of patients, nephrectomy...
Findings from a planned sub-analysis of clinical trial data comparing treatment options for renal cell carcinoma patients (RCC) with sacromatoid history were presented at the 2019 American Society of Clinical Oncology annual meeting. The observations shared suggested that a combination of atezolizumab...